Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
7 NC counties are under alert, including Johnston County.
Program
On WRAL at 6: Hidden fees in your childâs school lunch payment ð¨ð¸ 5 On Your Side shows you how to keep more money in your pocket
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Intellia Thera CS
(NQ:
NTLA
)
23.60
+0.42 (+1.81%)
Streaming Delayed Price
Updated: 10:06 AM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Intellia Thera CS
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
The 3 Leaders of the Gene Editing Revolution
July 08, 2022
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch.
Via
InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
July 08, 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.
Via
InvestorPlace
Do You Have Biotech FOMO? It Might Be Time To Pay Attention To These Names
July 06, 2022
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say.
Via
Investor's Business Daily
Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying
July 06, 2022
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say.
Via
Investor's Business Daily
Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis
June 24, 2022
Via
Benzinga
BMO Initiates Coverage On This Gene Editing Spearhead
June 17, 2022
Via
Benzinga
4 Analysts Have This to Say About Intellia Therapeutics
April 28, 2022
Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:NTLA) within the last quarter:
Via
Benzinga
Analyst Ratings for Intellia Therapeutics
June 16, 2022
Over the past 3 months, 7 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2022
June 16, 2022
Upgrades
Via
Benzinga
Analyst Ratings for Intellia Therapeutics
May 24, 2022
Over the past 3 months, 8 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
10 Biggest Price Target Changes For Monday
May 09, 2022
Morgan Stanley cut Guardant Health, Inc. (NASDAQ: GH) price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in pre-market trading.
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Preview For Intellia Therapeutics
May 04, 2022
Intellia Therapeutics (NASDAQ:NTLA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
How To Attend Intellia Therapeutics Q1 2022 Earnings Conference Call
May 02, 2022
Intellia Therapeutics (NASDAQ:NTLA) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
April 28, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
April 21, 2022
On Thursday, 236 companies hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
April 20, 2022
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...
Via
Benzinga
Good Entry Point for Biotech Stocks
April 04, 2022
Life science and biotech stocks had a good week with the most well-known ETFs up 3-4% for the week and off recent bottoms.
Via
Talk Markets
FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials
March 15, 2022
The FDA has outlined new draft guidance on what should be submitted in a clinical trial application and potentially concerning safety issues to track the genome editing products.
Via
Benzinga
Here's How Much $100 Invested In Intellia Therapeutics 5 Years Ago Would Be Worth Today
March 15, 2022
Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 19.59% on an annualized basis. Buying $100 In NTLA: 5 years ago, an investor could have...
Via
Benzinga
Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer
March 10, 2022
Intellia Therapeutics Inc's (NASDAQ: NTLA) CRISPR-powered T cell therapy has received an FDA orphan drug designation. The autologous T cell receptor therapy, dubbed...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2022
March 07, 2022
Upgrades According to Brookline Capital, the prior rating for Intellia Therapeutics Inc (NASDAQ:NTLA) was changed from Hold to Buy. In the fourth quarter, Intellia Therapeutics...
Via
Benzinga
63 Biggest Movers From Yesterday
March 04, 2022
Gainers Indonesia Energy Corporation Limited (NASDAQ: INDO) shares climbed 39.3% to close at $20.20 on Thursday after jumping around 35% on Wednesday. DBV Technologies S.A. (...
Via
Benzinga
44 Stocks Moving In Tuesday's Mid-Day Session
March 01, 2022
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) climbed 193% to $0.9962 after jumping 36% on Monday. GBS Inc. (NASDAQ: GBS) rose 73.3% to $0.7971 after declining around 9% on...
Via
Benzinga
80 Biggest Movers From Yesterday
March 02, 2022
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) jumped 78.5% to close at $0.6066 on Tuesday after jumping 36% on Monday. CTI BioPharma Corp. (NASDAQ: CTIC) surged 63...
Via
Benzinga
Analyst Ratings For Intellia Therapeutics
March 01, 2022
Over the past 3 months, 4 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and...
Via
Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
Via
Benzinga
Intellia Shares Updated Data On Gene Editing Durability In Rare Disease
March 01, 2022
Eight months after delivering promising biomarker data from one of the first CRISPR trials, Intellia Therapeutics Inc (NASDAQ: NTLA) presented additional data...
Via
Benzinga
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test
February 28, 2022
Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's After-Market Session
February 28, 2022
Gainers GBS (NASDAQ:GBS) stock rose 10.9% ...
Via
Benzinga
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.